Clinical Evaluation of the Effect of Aficamten on QT/QTc Interval in Healthy Participants

Concomitant Aficamten and Disopyramide in Symptomatic Obstructive Hypertrophic Cardiomyopathy

CK-4021586: A Novel Cardiac Myosin Inhibitor with An Alternative Mechanism of Action for the Treatment of HFpEF

Healthcare Resource Utilization and Costs of Non-Obstructive Hypertrophic Cardiomyopathy in the United States

Medication Adherence and Adverse Drug Effects Across Patients with Obstructive Hypertrophic Cardiomyopathy Receiving Pharmacotherapy

Association Between Race/Ethnicity and Outcomes in Patients With Nonobstructive Hypertrophic Cardiomyopathy

Understanding the Impact of Placebo on Patient-reported Health Status: An Analysis From SEQUOIA-HCM

Effect of Aficamten Treatment for Up to 72 Weeks on Cardiac Structure and Function in Patients with Obstructive Hypertrophic Cardiomyopathy: The SEQUOIA-HCM and FOREST-HCM CMR Sub-studies

Evaluation of Cytochrome P450 2C9, 2C19, and 2D6 Inhibition on the Pharmacokinetics of Aficamten in Healthy Participants

Concomitant Aficamten and Disopyramide in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy